Advertisements

Johnson & Johnson
JNJ,
-0.72%
stated Thursday {that a} South African Part 3 examine confirmed that its a booster shot of its COVID-19 vaccine was 85% efficient in stopping COVID-19-related hospitalization. The drug maker stated the examine, carried out by the South African Medical Analysis Council, was carried out from mid-November to mid-December, which is after omicron grew to become the dominant variant. “This provides to our rising physique of proof which reveals that the effectiveness of the Johnson & Johnson COVID-19 vaccine stays sturdy and secure over time, together with towards circulating variants reminiscent of Omicron and Delta,” stated Mathai Mammen, international head of J&J’s Janssen Analysis & Improvement LLC. J&J’s inventory, which was little modified in premarket buying and selling, has gained 9.0% this yr, whereas the Dow Jones Industrial Common
DJIA,
-0.16%
has superior 19.2%.

Source link